Virtual Reality–Assisted Therapy Compared to Cognitive Behavioral Therapy for Patients With Treatment-Resistant Schizophrenia: Assessor-Blind Randomized Controlled Trial
JMIR Mental Health · 16.09.2026 · 13 · e106791-e106791
DOI: 10.2196/106791 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift JMIR Mental Health, online erschienen am 16.09.2026. Verfasst von Mélissa Beaudoin und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry and Addictology, Université de Montréal, 2900, boul. Édouard-Montpetit, Montreal, QC, H3T 1J4, Canada, 1 514-251-4000 ext 39…. Hauptthemen laut MEDLINE: Cognitive Behavioral Therapy, Hallucinations, Schizophrenia, Treatment-Resistant, Virtual Reality Exposure Therapy. Die Arbeit nennt 56 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Background
Auditory verbal hallucinations (AVH) are among the most disabling symptoms of schizophrenia and often persist despite treatment. Virtual reality–assisted therapies (VRTs) are a new generation of relational interventions for AVH, but comparative evidence against active interventions is currently lacking.
Objective
This study aimed to assess whether VRT (9 sessions) is superior to a short course of cognitive behavioral therapy (CBT) targeting AVH (9 sessions) in reducing AVH in individuals with treatment-resistant schizophrenia.
Methods
In this assessor-blind, parallel-group randomized controlled trial conducted from 2019 to 2026 at an academic center in Montreal (Canada), adults with schizophrenia or schizoaffective disorder and persistent AVH were either referred by their health care team or self-referred. A total of 136 participants were randomly assigned 1:1 to VRT or CBT, stratified by sex and clozapine use status. Both 9-session interventions targeted maladaptive beliefs and relationships with voices and were administered by trained psychotherapists. The predetermined primary outcome was the evolution of AVH severity over time, measured at baseline, post treatment, and 3 months post therapy using the auditory hallucination subscale of the Psychotic Symptoms Rating Scale. Secondary outcomes notably included the general psychotic symptomatology measured using the Positive and Negative Syndrome Scale. Linear mixed-effects models were used to assess time-by-treatment interactions. Psychotherapy sessions and assessments were conducted primarily in person, with CBT being occasionally delivered via videoconferencing during the COVID-19 pandemic.
Results
Participants had a mean age of 40.3 (SD 12.8) years, 63.2% (86/136) were male, and 56.6% (77/136) received clozapine. Intention-to-treat analyses (VRT, n=67; CBT, n=69) showed a significant time-by-treatment interaction favoring VRT ( P =.013) with a moderate effect size at 3 months post therapy (Cohen d =0.614). Both therapies showed significant within-group improvements in the primary outcome, with large effect sizes for VRT (Cohen d =0.81 post therapy and Cohen d =1.17 at 3 months) and moderate for CBT (Cohen d =0.58 post therapy and Cohen d =0.39 at 3 months). While there were no between-group differences for secondary outcomes, within-group improvements were observed in psychotic symptoms, emotional regulation, and voice acceptance for both therapies, and VRT also reduced maladaptive beliefs about voices and improved self-esteem.
Conclusions
VRT outperformed a targeted short course of CBT in reducing persistent AVH for up to 3 months after the intervention in a North American population with treatment-resistant schizophrenia. Improvements were also seen in some secondary outcomes, such as general psychotic symptomatology, and those were similar for both interventions. Overall, these findings support the value of VRT as a personalized and clinically effective intervention.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Psychiatry and Addictology, Université de Montréal, 2900, boul. Édouard-Montpetit, Montreal, QC, H3T 1J4, Canada, 1 514-251-4000 ext 3925.
- Institut universitaire en santé mentale de Montréal, Montreal, QC, Canada.
- Centre hospitalier de l'Université de Montréal, Montreal, QC, Canada.
ORCID-Profile: Mélissa Beaudoin, Stéphane Potvin, Sabrina Giguère, Charles-Édouard Giguère, Frederick Aardema, Olivier Lipp, Pierre Lalonde, Emmanuel Stip, Alexandra Fortier, Alexandre Dumais
Zitieren
APA
Beaudoin, M., Potvin, S., Giguère, S., Giguère, C. É., Aardema, F., Abdel-Baki, A., De Benedictis, L., Lipp, O., Lalonde, P., Stip, E., Fortier, A., Phraxayavong, K., & Dumais, A. (2026). Virtual Reality–Assisted Therapy Compared to Cognitive Behavioral Therapy for Patients With Treatment-Resistant Schizophrenia: Assessor-Blind Randomized Controlled Trial. JMIR Mental Health, 13, e106791-e106791. https://doi.org/10.2196/106791
Vancouver
Beaudoin M, Potvin S, Giguère S, Giguère CÉ, Aardema F, Abdel-Baki A, et al. Virtual Reality–Assisted Therapy Compared to Cognitive Behavioral Therapy for Patients With Treatment-Resistant Schizophrenia: Assessor-Blind Randomized Controlled Trial. JMIR Mental Health. 2026;13:e106791-e106791. doi:10.2196/106791
BibTeX
@article{Beaudoin2026,
author = {Beaudoin, Mélissa and Potvin, Stéphane and Giguère, Sabrina and Giguère, Charles-Édouard and Aardema, Frederick and Abdel-Baki, Amal and De Benedictis, Luigi and Lipp, Olivier and Lalonde, Pierre and Stip, Emmanuel and Fortier, Alexandra and Phraxayavong, Kingsada and Dumais, Alexandre},
title = {Virtual Reality–Assisted Therapy Compared to Cognitive Behavioral Therapy for Patients With Treatment-Resistant Schizophrenia: Assessor-Blind Randomized Controlled Trial},
journal = {JMIR Mental Health},
year = {2026},
volume = {13},
pages = {e106791--e106791},
doi = {10.2196/106791}
}
EUVIMED